APAF1

Across TCGA pan-cancer cohorts, APAF1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated APAF1 data layer compared with 28 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher APAF1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated APAF1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where APAF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.600	0.866	<.001	66	view →
UCEC	DFS	Tertile	II,III,IV	1.000	0.492	.008	12	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	6	view →
LUAD	OS	Median	II,III,IV	0.327	0.844	.005	6	view →
HNSC	OS	Quartile	IV	0.940	0.665	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

APAF1–CCRCC (DFS)

Open the CCRCC breakdown →